Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Admilparant - Bristol-Myers Squibb

Next Previous
Drug Profile

Admilparant - Bristol-Myers Squibb

Alternative Names: BMS-986278

Latest Information Update: 13 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antifibrotics; Carbamates; Cyclohexanecarboxylic acids; Hepatoprotectants; Pyridines; Small molecules; Triazoles
  • Mechanism of Action LPAR1 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic pulmonary fibrosis; Pulmonary fibrosis
  • Phase I Liver disorders

Most Recent Events

  • 14 Jun 2026 Bristol-Myers Squibb completes a phase I trial in Healthy volunteers in USA (PO) (NCT07422298)
  • 20 May 2026 Drug interactions and adverse events data from a phase I trial in healthy volunteers presented at the 122nd International Conference of the American Thoracic Society (ATS-2026)
  • 15 May 2026 Pharmacodynamics data from a preclinical trial in Pulmonary fibrosis presented at the 122nd International Conference of the American Thoracic Society (ATS-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top